Global Frontotemporal Disorders Treatment Market - 2022-2029

Market Overview

The Frontotemporal Disorders Treatment Market size was valued at USD 721.4 million in 2021 and is estimated to reach at a compound annual growth rate (CAGR) of 6.50% over the forecast period 2022 to 2029.

Frontotemporal disorder, commonly known as Pick disease, is a form of dementia that is caused by a family of brain disorders known as frontotemporal lobar degeneration (FTLD). Frontotemporal dementia is a rare type of dementia that causes behavior and language problems. Dementia is associated with disorders of mental abilities caused by some changes and damage in the brain and affects the front and sides of the brain.

The Frontotemporal Disorders Treatment Market study analysis offers an in-depth outlook on the market containing both quantitative, and qualitative data. It gives an outlook and forecast of the global market based on the Frontotemporal Disorders Treatment Market segmentation by drug class, procedure, and Distribution Channel. It also provides market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global Frontotemporal Disorders Treatment Market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Market Dynamics

The global frontotemporal disorders treatment market growth is driven by certain factors such as the rising prevalence of dementia and other frontotemporal disorders, increasing drug development grants, and funding by the government as well as non-government organizations are the key factors driving the market growth.

The rising technological advancements, is expected to drive the global frontotemporal disorders treatment market during the forecast period;

As per the World Health Organization, about 50 Mn people have dementia, and there are around 10 Mn new cases annually, which is anticipated to boost the industry growth.

Frontotemporal dementia accounts for 2-5% of the overall dementia cases. The prevalence of dementia is projected to be triple by 2050. As per the Dementia Statistics Organization, the number of people living with dementia is projected to increase by 204% from 50 million in 2018 to 152 million by 2050. The increasing number of dementia cases will further increase the cases of frontotemporal dementia, which is expected to drive more demand for frontotemporal disorders treatment drugs and medications.

Also, the rising government support and funding for research activities to find the treatment of target disease is expected to drive the growth of the market. Several organizations are involved in developing new medications, including the National Institute of Health (NIH), Alzheimer's Association, and National Institute on Aging. In 2019, the NIH spent around US$ 387 million on research projects for Alzheimer's Disease-Related Dementias (ADRD). These initiatives are expected to boost market growth over the forecast period.

Lack of awareness towards the target disease in a developing country are likely to hinder the market growth

However, lack of proper diagnosis and higher chances of misunderstanding with Alzheimer's disease is restraining the growth of the frontotemporal dementia treatment market. Additionally poor treatment regimens lack of novel therapies is also limiting the Frontotemporal dementia treatment market growth.

Industry Analysis

The global frontotemporal disorders treatment market provides in-depth analysis of the market based on various industry factors such as porter's five force analysis, supply chain analysis, regulatory analysis, pricing analysis etc, unmet needs.

Segmentation Analysis

The antidepressants segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Based on drug class, the global frontotemporal disorders treatment market is segmented into antipsychotics, cognitive enhancers, CNS stimulants, antidepressants, and others. Among these, antidepressants are expected to show a lucrative opportunity over the forecast period. Antidepressant drugs are mainly used for the treatment of depressive disorders and other conditions, such as dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, neuropathic pain, eating disorders, and chronic pain, among others. Several other types of antidepressants are widely prescribed by physicians to manage patient health effectively. Also, (SSRIs) selective serotonin reuptake inhibitors prove beneficial for the treatment of frontotemporal disorders.

In October 2018, Lundbeck launched Brintellix tablets, which are used for the treatment of Major Depressive Disorder in India. Furthermore, in April 2019, Lupin launched antidepressant Fluoxetine tablets in the American market. The tablets are indicated for the treatment of the major depressive disorder, and obsessive-compulsive disorder. Thus, owing to the rising patient pool and recent product launches, the market is expected to witness high growth across the globe over the forecast period.

Geographical Analysis

North America region holds the largest market share of the global frontotemporal disorders treatment market

North America region is dominating the global frontotemporal disorders treatment market accounting for the largest market share in 2019, owing to a large presence of advanced healthcare facilities and infrastructure in developed countries, such as the United States. Also, the rising prevalence of frontotemporal disorders in this region is driving the growth of the market. For instance, according to the National Institute of Neurological Disorders and Stroke, Alzheimer's disease alone, as one dementia disorder, affects over 5 million people in the United States. The toll on individuals, society, and caregivers is enormous and is expected to increase as the population ages. Frontotemporal dementia falls under rare diseases or orphan indications.

In the United States, around 30,000 to 40,000 patients are suffering from frontotemporal disorders. Treatment of frontotemporal disorders falls under the Orphan Drug Act of 1983 as orphan drug indications are those which affect less than 200,000 people in the U.S. along with similar legislation in Europe. Orphan drug designation to FTD allows the continuation of clinical trials and development of a drug with commercial incentives, prioritizing consultation by FDA on clinical studies and reduction in regulatory fees.

Competitive Landscape

The global frontotemporal disorders treatment market is competitive and consists of several major players in the market. Some of the key players which are contributing to the growth of the market include Johnson & Johnson, Apotex Inc., Auro Pharma, Pfizer Inc., Teva Pharmaceuticals USA, Inc., AstraZeneca plc., Mylan N.V., Sanofi S.A., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the frontotemporal disorders treatment market globally. For instance, on June 15th, 2020, ACADIA Pharmaceuticals Inc. submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to support a potential new indication for NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). The FDA previously granted Breakthrough Therapy Designation for pimavanserin for the treatment of hallucinations and delusions associated with DRP.

Key Companies to Watch

Pfizer Inc

Overview: Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

Product Portfolio: ZFP-TFs to down-regulate the expression of tau, a protein associated with Alzheimer's disease and frontotemporal dementia (FTD).

The global frontotemporal disorders treatment market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.